The most common grade 3 to 4 adverse events ( graded according to version 3.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events ) among patients receiving sunitinib were thrombocytopenia , diarrhea , mucositis , fatigue , and hypertension .